Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Buy
52
VCYT Quote, Financials, Valuation and Earnings
Last price:
$29.03
Seasonality move
:
22.55%
Day range:
$28.42 - $29.10
52-week range:
$19.73 - $47.32
Dividend yield:
0%
P/E ratio:
71.22x
P/S ratio:
4.98x
P/B ratio:
1.91x
Volume:
966.7K
Avg. volume:
1.1M
1-year change:
26.75%
Market cap:
$2.3B
Revenue:
$445.8M
EPS (TTM):
$0.41
Analysts' Opinion
-
Consensus RatingVeracyte has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $40.50, Veracyte has an estimated upside of 38.7% from its current price of $29.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.00 representing 100% downside risk from its current price of $29.00.
Fair Value
-
According to the consensus of 10 analysts, Veracyte has 38.7% upside to fair value with a price target of $40.50 per share.
VCYT vs. S&P 500
-
Over the past 5 trading days, Veracyte has underperformed the S&P 500 by -6.64% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Veracyte does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Veracyte has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Veracyte reported revenues of $114.5M.
Earnings Growth
-
Veracyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Veracyte reported earnings per share of $0.09.
Enterprise value:
2B
EV / Invested capital:
1.67x
Price / LTM sales:
4.98x
EV / EBIT:
69.38x
EV / Revenue:
4.31x
PEG ratio (5yr expected):
-0.48x
EV / Free cash flow:
25.49x
Price / Operating cash flow:
29.43x
Enterprise value / EBITDA:
38.41x
Gross Profit (TTM):
$315.2M
Return On Assets:
2.61%
Net Income Margin (TTM):
7.13%
Return On Equity:
2.85%
Return On Invested Capital:
2.85%
Operating Margin:
1.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $311.2M | $375.5M | $463.4M | $96.8M | $114.5M | |
| Gross Profit | $187.8M | $240.8M | $315.2M | $62.5M | $79.5M | |
| Operating Income | -$32.4M | -$12.4M | $24.8M | -$3.7M | $1.2M | |
| EBITDA | -$3.9M | -$46.1M | $52M | $1.9M | $6.5M | |
| Diluted EPS | -$0.41 | -$0.94 | $0.41 | -$0.02 | $0.09 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $362.1M | $238.5M | $251.5M | $290.4M | $383.2M | |
| Total Assets | $1B | $1.2B | $1.2B | $1.2B | $1.3B | |
| Current Liabilities | $32.7M | $62.5M | $56M | $58.1M | $75.1M | |
| Total Liabilities | $50.9M | $88.4M | $75.9M | $81.4M | $120.5M | |
| Total Equity | $974.2M | $1.1B | $1.1B | $1.1B | $1.2B | |
| Total Debt | $863K | $1.1M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $14.2M | $37.4M | $89.4M | -$9M | $5.4M | |
| Cash From Investing | -$2.9M | -$6.1M | -$111M | $2.9M | -$51.8M | |
| Cash From Financing | $3.2M | $288K | -$716K | -$864K | -$6.5M | |
| Free Cash Flow | $7.1M | $26.3M | $78.5M | -$11.1M | $3.5M | |
VCYT
Sector
Market Cap
$2.3B
$34.2M
Price % of 52-Week High
61.71%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
24.79%
-41.71%
Beta (5-Year)
2.145
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$29.52
200-day SMA
Sell
Level
$35.05
Bollinger Bands (100)
Sell
Level
30.16 - 41.38
Chaikin Money Flow
Buy
Level
37.1M
20-day SMA
Sell
Level
$30.47
Relative Strength Index (RSI14)
Sell
Level
42.30
ADX Line
Sell
Level
17.38
Williams %R
Neutral
Level
-61.6438
50-day SMA
Sell
Level
$30.79
MACD (12, 26)
Sell
Level
-0.69
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
47.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (15.0951)
Buy
CA Score
(Annual)
Level (1.7006)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-5.0901)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Stock Forecast FAQ
In the current month, VCYT has received 7 Buy ratings 2 Hold ratings, and 1 Sell ratings. The VCYT average analyst price target in the past 3 months is $40.50.
-
Where Will Veracyte Stock Be In 1 Year?
According to analysts, the consensus estimate is that Veracyte share price will rise to $40.50 per share over the next 12 months.
-
What Do Analysts Say About Veracyte?
Analysts are divided on their view about Veracyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Veracyte is a Sell and believe this share price will drop from its current level to $29.00.
-
What Is Veracyte's Price Target?
The price target for Veracyte over the next 1-year time period is forecast to be $40.50 according to 10 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is VCYT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Veracyte is a Buy. 7 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VCYT?
You can purchase shares of Veracyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Veracyte shares.
-
What Is The Veracyte Share Price Today?
Veracyte was last trading at $29.03 per share. This represents the most recent stock quote for Veracyte. Yesterday, Veracyte closed at $29.00 per share.
-
How To Buy Veracyte Stock Online?
In order to purchase Veracyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
99
SOC alert for May 20
Sable Offshore [SOC] is up 14.35% over the past day.
Buy
52
RGC alert for May 20
Regencell Bioscience Holdings [RGC] is down 10.93% over the past day.
Sell
40
GWLIF alert for May 20
Great-West Lifeco [GWLIF] is down 10.31% over the past day.
